Cencora, Inc. (NYSE:COR) Shares Sold by AlphaCore Capital LLC

AlphaCore Capital LLC trimmed its holdings in Cencora, Inc. (NYSE:COR) by 12.6% in the third quarter, Holdings Channel.com reports. The institutional investor owned 1,657 shares of the company’s stock after selling 238 shares during the quarter. AlphaCore Capital LLC’s holdings in Cencora were worth $373,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Price T Rowe Associates Inc. MD purchased a new stake in Cencora during the 1st quarter valued at approximately $2,183,619,000. Boston Partners acquired a new position in shares of Cencora in the first quarter valued at approximately $1,001,269,000. Pacer Advisors Inc. raised its stake in shares of Cencora by 6,855.3% during the third quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company’s stock worth $464,874,000 after purchasing an additional 2,035,679 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Cencora during the first quarter worth $223,970,000. Finally, DekaBank Deutsche Girozentrale purchased a new position in Cencora in the 1st quarter valued at $128,825,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Price Performance

Cencora stock opened at $245.50 on Friday. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The firm has a market capitalization of $48.38 billion, a PE ratio of 32.69, a P/E/G ratio of 1.60 and a beta of 0.44. The firm’s 50-day simple moving average is $232.96 and its 200 day simple moving average is $231.37. Cencora, Inc. has a 52 week low of $195.83 and a 52 week high of $251.56.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.90%. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date is Friday, November 15th. Cencora’s dividend payout ratio (DPR) is 29.29%.

Analyst Ratings Changes

COR has been the subject of several recent analyst reports. Wells Fargo & Company raised their target price on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 1st. Leerink Partners reduced their price objective on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. Robert W. Baird boosted their target price on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Finally, UBS Group upped their price objective on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Cencora has an average rating of “Moderate Buy” and a consensus target price of $271.20.

Insider Buying and Selling

In related news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the transaction, the chairman now owns 306,752 shares of the company’s stock, valued at approximately $74,283,064.32. The trade was a 6.55 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 15.80% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.